NHS to Block Eli Lilly's Alzheimer's Drug Donanemab Over Cost Concerns: Report
The National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, will rule that it is too expensive
Written By : Farhat Nasim
Published On 2024-10-23 09:13 GMT | Update On 2024-10-23 09:13 GMT
Advertisement
Bengaluru: Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients, the Telegraph reported on Tuesday.
British regulators are expected to declare the drug safe for use on Wednesday, but the National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, will immediately rule that it is too expensive for NHS patients, the newspaper reported.
Eli Lilly, NHS and NICE did not immediately respond to Reuters' requests for a comment.
The Telegraph has previously reported in August that donanemab would be rejected by NICE and blocked for use by the NHS.
Scientists have hailed donanemab as the "best ever" treatment for Alzheimer's disease, reportedly being even more effective at slowing the progression of the condition than previous treatments.
The U.S. Food and Drug Administration approved donanemab for the treatment of early Alzheimer's in July.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.